Proving the potential success of biosimilars
The total cumulative export value of Remsima® reached KRW 1 trillion in 2016, which was a great achievement in the biopharmaceutical history of Korea. In addition, Celltrion Healthcare managed to launch Remsima®(Inflectra®) in the United States, which is known for having the world’s top pharmaceutical market, and Truxima®, the world's first oncology mAB biosimilar, in Europe, proving that biosimilars have the potential for success in the global markets.